1500 E Medical Center Dr
Ann Arbor, MI 48109
Available to mentor
Dr. Benjamin Rosen is an Associate Professor and the Medical Physcs Residency Program Director within the Department of Radiation Oncology at Michigan Medicine. He received his PhD from the University of WIsconsin in 2015 with thesis entitled, "Advanced radiochromic film methodologies for quantitative dosimetry of small and nonstandard fields". Dr. Rosen was an Academic Clinical Medical Physics Resident at Michigan Medicine from 2015-2018 and has worked on numerous nationally funded research projects and taught many learners in Ann Arbor and beyond.
RadOnc Bio
-
ResidentUniversity of Michigan Medical School, Physics, 2017
-
PhDUniversity of Wisconsin - Madison, Madison, 2015
-
MSUniversity of Wisconsin - Madison, Madison, 2012
-
BSUniversity of Texas at Austin, Austin, 2008
- Advanced imaging analysis to support adaptive radiotherapy in head and neck, brain, and liver tumors and surrounding normal tissues.
- Building predictive models for risk assessments of tumor control and normal tissue complication for various treatment combinations, including immune checkpoint inhibition therapy in combination with stereotactic ablative body radiotherapy.
- Investigations of normal tissue tolerance and treatment efficacy in the re-irradation setting
-
Nieto JD, Chang DT, Paradis KC, DuRussel E, Matuszak MM, Rosen BS, Prisciandaro JI, Matrosic C, Kashani R, Evans JR, Jackson WC, Lawrence TS, Jolly S, Mierzwa ML, Mayo C. International Journal of Radiation Oncology • Biology • Physics, 2024 Oct; 120 (2): e171Proceeding / Abstract / PosterApplication of Standardized Tissue Repair Discount Factors to Guide Spinal Cord Dose in Reirradiation
DOI:10.1016/j.ijrobp.2024.07.385 -
Regan SN, Aryal MP, Suresh K, Rosen BS, Walline H, Prince ME, Malloy K, Casper K, Shuman A, Chinn SB, Heft-Neal ME, Swiecicki PL, Worden F, Shah JL, Cao Y, Brenner C, Mierzwa ML. International Journal of Radiation Oncology • Biology • Physics, 2024 Oct; 120 (2): s131Proceeding / Abstract / PosterImaging Metrics and HPV ctDNA Kinetics in a Phase II Immuno-Chemoradiation Trial for Locoregionally Advanced p16+ Oropharynx Cancer
DOI:10.1016/j.ijrobp.2024.07.238 -
Mayo C, Su S, Rosen BS, Covington E, Zhang Z, Lawrence TS, Fuller CD, Brock KK, Shah JL, Mierzwa ML. International Journal of Radiation Oncology • Biology • Physics, 2024 Oct; 120 (2): s41 - s42.Proceeding / Abstract / PosterNovel Statistical-AI Method to Automate Discovery of Predictive Factors and Thresholds for 3 Year Survival, Dysphagia and Xerostomia for Patients with Head and Neck Cancers
DOI:10.1016/j.ijrobp.2024.07.062 -
Rosen B, Kim M. 2024 May 16;PresentationEstimating Tissue Recovery Factors for CNS/Brain Re-irradiation
-
Rosen B, Bentzen S. 2024 May 16;PresentationTime-dependent Tissue Repair Factors
-
Mayo CS, Su S, Rosen B, Covington E, Zhang Z, Lawrence T, Kudner R, Fuller C, Brock KK, Shah J, Mierzwa MM. medRxiv,PreprintData Farming to Table: Combined Use of a Learning Health System Infrastructure, Statistical Profiling, and Artificial Intelligence for Automating Toxicity and 3-year Survival for Quantified Predictive Feature Discovery from Real-World Data for Patients Having Head and Neck Cancers
DOI:10.1101/2023.10.24.23297349 -
Su S, Mayo C, Rosen BS, Covington E, Zhang Z, Bryant AK, Allen SG, Rivera KAM, Edwards DM, Takayesu J, Herr DJ, Miller SR, Regan SN, Dykstra MP, Sun GY, Elaimy AL, Mierzwa ML. International Journal of Radiation Oncology • Biology • Physics, 2023 Oct; 117 (2): e628Proceeding / Abstract / PosterUse of Explainable AI Algorithm Revealing Longitudinal Changes in Practice Patterns and Toxicity Models
DOI:10.1016/j.ijrobp.2023.06.2020 -
Allen SG, Rosen BS, Aryal M, Cao Y, Schipper MJ, Wong KK, Casper KA, Chinn SB, Malloy KM, Prince ME, Rosko AJ, Shuman AG, Spector ME, Stucken CL, Swiecicki PL, Worden FP, Brenner JC, Schonewolf CA, Elliott DA, Mierzwa ML, Shah JL. Int J Radiat Oncol Biol Phys, 2023 Sep 1; 117 (1): 171 - 180.Journal ArticleInitial Feasibility and Acute Toxicity Outcomes From a Phase 2 Trial of 18F-Fluorodeoxyglucose Positron Emission Tomography Response-Based De-escalated Definitive Chemoradiotherapy for p16+ Oropharynx Cancer: A Planned Interim Analysis.
DOI:10.1016/j.ijrobp.2023.03.043 PMID: 36931572